Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tobacco Use Disorder | 18 | 2020 | 432 | 3.460 |
Why?
|
| Smoking | 14 | 2020 | 1452 | 1.830 |
Why?
|
| Smoking Cessation | 14 | 2020 | 1034 | 1.460 |
Why?
|
| Cues | 15 | 2017 | 654 | 1.400 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 2223 | 1.260 |
Why?
|
| Neurofeedback | 5 | 2016 | 34 | 1.240 |
Why?
|
| Craving | 5 | 2017 | 200 | 1.230 |
Why?
|
| Substance Withdrawal Syndrome | 6 | 2018 | 435 | 0.950 |
Why?
|
| Brain | 8 | 2018 | 2176 | 0.910 |
Why?
|
| Behavior, Addictive | 4 | 2015 | 317 | 0.910 |
Why?
|
| Functional Neuroimaging | 5 | 2014 | 82 | 0.900 |
Why?
|
| Alcohol Deterrents | 1 | 2019 | 86 | 0.660 |
Why?
|
| Opioid-Related Disorders | 4 | 2021 | 298 | 0.650 |
Why?
|
| Motivation | 4 | 2018 | 561 | 0.640 |
Why?
|
| Marijuana Abuse | 4 | 2018 | 251 | 0.620 |
Why?
|
| Gyrus Cinguli | 3 | 2013 | 113 | 0.580 |
Why?
|
| Prefrontal Cortex | 7 | 2020 | 640 | 0.580 |
Why?
|
| Quinoxalines | 3 | 2015 | 78 | 0.570 |
Why?
|
| Motivational Interviewing | 2 | 2016 | 40 | 0.570 |
Why?
|
| Benzazepines | 3 | 2015 | 104 | 0.560 |
Why?
|
| Cocaine-Related Disorders | 5 | 2013 | 504 | 0.550 |
Why?
|
| Medication Adherence | 2 | 2019 | 335 | 0.550 |
Why?
|
| Psychotherapy, Group | 1 | 2016 | 55 | 0.540 |
Why?
|
| Veterans Health | 1 | 2016 | 62 | 0.530 |
Why?
|
| Adult | 32 | 2021 | 21403 | 0.500 |
Why?
|
| Life Change Events | 2 | 2013 | 223 | 0.500 |
Why?
|
| Galvanic Skin Response | 1 | 2014 | 67 | 0.480 |
Why?
|
| Young Adult | 17 | 2020 | 5717 | 0.480 |
Why?
|
| Olfactory Perception | 1 | 2014 | 20 | 0.470 |
Why?
|
| Gray Matter | 1 | 2014 | 57 | 0.460 |
Why?
|
| Patient Compliance | 1 | 2016 | 402 | 0.450 |
Why?
|
| Heart Rate | 2 | 2014 | 568 | 0.430 |
Why?
|
| Female | 35 | 2021 | 38074 | 0.430 |
Why?
|
| Stress, Psychological | 5 | 2013 | 824 | 0.420 |
Why?
|
| Male | 33 | 2021 | 37321 | 0.420 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2012 | 689 | 0.400 |
Why?
|
| Transcranial Magnetic Stimulation | 4 | 2020 | 413 | 0.390 |
Why?
|
| Alcoholism | 1 | 2019 | 1109 | 0.370 |
Why?
|
| Middle Aged | 23 | 2020 | 21147 | 0.370 |
Why?
|
| Nicotinic Agonists | 4 | 2015 | 111 | 0.370 |
Why?
|
| Buprenorphine | 2 | 2021 | 67 | 0.350 |
Why?
|
| Humans | 39 | 2021 | 68618 | 0.340 |
Why?
|
| Nicotine | 4 | 2015 | 350 | 0.320 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.320 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 439 | 0.310 |
Why?
|
| Pilot Projects | 5 | 2016 | 1342 | 0.300 |
Why?
|
| Adolescent | 14 | 2020 | 8912 | 0.290 |
Why?
|
| Varenicline | 4 | 2015 | 98 | 0.280 |
Why?
|
| Psychotic Disorders | 2 | 2016 | 157 | 0.210 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 1506 | 0.210 |
Why?
|
| Brain Mapping | 3 | 2015 | 532 | 0.210 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2018 | 189 | 0.200 |
Why?
|
| Time Factors | 6 | 2020 | 4655 | 0.200 |
Why?
|
| Arousal | 2 | 2013 | 168 | 0.200 |
Why?
|
| Prescription Drugs | 2 | 2013 | 71 | 0.190 |
Why?
|
| Imagination | 2 | 2012 | 38 | 0.190 |
Why?
|
| Memory | 2 | 2013 | 214 | 0.190 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 415 | 0.190 |
Why?
|
| Drug Overdose | 1 | 2021 | 67 | 0.190 |
Why?
|
| Smoking Prevention | 4 | 2015 | 259 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 101 | 0.180 |
Why?
|
| Veterans | 2 | 2019 | 904 | 0.180 |
Why?
|
| Disulfiram | 1 | 2019 | 22 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 131 | 0.160 |
Why?
|
| Smokers | 2 | 2018 | 200 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2018 | 295 | 0.160 |
Why?
|
| Double-Blind Method | 7 | 2020 | 1738 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 184 | 0.160 |
Why?
|
| Age Factors | 2 | 2014 | 1864 | 0.160 |
Why?
|
| Naltrexone | 1 | 2019 | 195 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 782 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 711 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 951 | 0.140 |
Why?
|
| United States | 3 | 2019 | 7367 | 0.140 |
Why?
|
| Neural Inhibition | 1 | 2017 | 80 | 0.140 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2016 | 151 | 0.130 |
Why?
|
| Nerve Net | 1 | 2018 | 181 | 0.130 |
Why?
|
| Vilazodone Hydrochloride | 1 | 2015 | 6 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2016 | 7029 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 3259 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 257 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 468 | 0.130 |
Why?
|
| Gender Identity | 1 | 2015 | 47 | 0.120 |
Why?
|
| Menstrual Cycle | 1 | 2015 | 64 | 0.120 |
Why?
|
| Aftercare | 1 | 2016 | 114 | 0.120 |
Why?
|
| Parahippocampal Gyrus | 1 | 2014 | 15 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.120 |
Why?
|
| Neural Pathways | 2 | 2014 | 324 | 0.120 |
Why?
|
| Linear Models | 2 | 2013 | 521 | 0.120 |
Why?
|
| Progesterone | 1 | 2015 | 115 | 0.120 |
Why?
|
| Globus Pallidus | 1 | 2014 | 64 | 0.120 |
Why?
|
| Thalamus | 1 | 2014 | 82 | 0.120 |
Why?
|
| Organ Size | 1 | 2014 | 242 | 0.120 |
Why?
|
| Estradiol | 1 | 2015 | 176 | 0.120 |
Why?
|
| Parietal Lobe | 1 | 2014 | 59 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1054 | 0.110 |
Why?
|
| Amygdala | 1 | 2014 | 159 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2016 | 3705 | 0.110 |
Why?
|
| Propranolol | 1 | 2013 | 103 | 0.110 |
Why?
|
| Social Work | 1 | 2013 | 27 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7277 | 0.100 |
Why?
|
| Physical Examination | 1 | 2013 | 152 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.100 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2012 | 52 | 0.100 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2012 | 128 | 0.100 |
Why?
|
| Body Temperature | 1 | 2012 | 116 | 0.100 |
Why?
|
| Ovary | 1 | 2012 | 99 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2013 | 156 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 2 | 2011 | 221 | 0.100 |
Why?
|
| Dominance, Cerebral | 1 | 2011 | 65 | 0.100 |
Why?
|
| Neurotic Disorders | 1 | 2011 | 13 | 0.100 |
Why?
|
| Learning | 1 | 2013 | 186 | 0.090 |
Why?
|
| Child Abuse | 1 | 2013 | 186 | 0.090 |
Why?
|
| Educational Status | 1 | 2011 | 273 | 0.090 |
Why?
|
| Biofeedback, Psychology | 1 | 2010 | 23 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 291 | 0.090 |
Why?
|
| Employment | 1 | 2011 | 154 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1553 | 0.090 |
Why?
|
| Bupropion | 1 | 2010 | 63 | 0.090 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 57 | 0.090 |
Why?
|
| Evoked Potentials, Motor | 1 | 2010 | 63 | 0.090 |
Why?
|
| Emotions | 1 | 2011 | 244 | 0.090 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 426 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2010 | 143 | 0.090 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2010 | 92 | 0.080 |
Why?
|
| Movement | 1 | 2010 | 179 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 334 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2012 | 296 | 0.080 |
Why?
|
| Methylphenidate | 1 | 2010 | 97 | 0.080 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2010 | 152 | 0.080 |
Why?
|
| Conditioning, Operant | 1 | 2010 | 241 | 0.080 |
Why?
|
| Motor Cortex | 1 | 2010 | 158 | 0.080 |
Why?
|
| Aged | 4 | 2020 | 14862 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 1266 | 0.080 |
Why?
|
| Child | 2 | 2013 | 6405 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 1242 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2021 | 51 | 0.050 |
Why?
|
| South Carolina | 2 | 2021 | 2752 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2800 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Oxygen | 2 | 2012 | 386 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 498 | 0.030 |
Why?
|
| Transdermal Patch | 1 | 2015 | 21 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 152 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 3187 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 267 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 235 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 148 | 0.030 |
Why?
|
| Volition | 1 | 2012 | 16 | 0.030 |
Why?
|
| Individuality | 1 | 2012 | 44 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 189 | 0.030 |
Why?
|
| Cannabinoids | 1 | 2012 | 90 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 219 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2012 | 229 | 0.020 |
Why?
|
| Computer Systems | 1 | 2010 | 42 | 0.020 |
Why?
|
| Personality | 1 | 2011 | 66 | 0.020 |
Why?
|
| Sex Offenses | 1 | 2013 | 170 | 0.020 |
Why?
|
| Aggression | 1 | 2011 | 98 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4848 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 56 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2010 | 120 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 280 | 0.020 |
Why?
|
| Impulsive Behavior | 1 | 2011 | 85 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 21 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2010 | 150 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1040 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2009 | 106 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2011 | 291 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2009 | 79 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1426 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 536 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 2010 | 297 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 714 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 948 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1753 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 955 | 0.020 |
Why?
|
| Cocaine | 1 | 2011 | 555 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1465 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2077 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2279 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 5731 | 0.010 |
Why?
|